Shots:
- Amgen & AstraZeneca have reported the top-line P-III (CROSSING) trial results assessing Tezspire at one of two doses (tezepelumab-ekko; SC, Q4W) vs PBO in pts living with eosinophilic esophagitis (EoE)
- Trial showed improvements across co-1EPs (histologic remission, and the frequency & severity of dysphagia) & key 2EPs at Wk. 24 which were sustained through Wk. 52; data to be shared with regulatory authorities & presented in the meeting
- Tezspire is an human monoclonal antibody that blocks thymic stromal lymphopoietin, a key cytokine driving multiple inflammatory pathways linked to severe asthma, CRSwNP, COPD and EoE
Ref: PRnewswire | Image: AstraZeneca & Amgen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
